STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 83 filers reported holding STEMLINE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 6.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $285,000 | -62.2% | 26,819 | -45.5% | 0.01% | -67.4% |
Q2 2019 | $753,000 | +370.6% | 49,172 | +294.3% | 0.04% | +330.0% |
Q1 2019 | $160,000 | -55.1% | 12,472 | -42.0% | 0.01% | -37.5% |
Q3 2018 | $356,000 | -27.5% | 21,497 | -29.8% | 0.02% | -20.0% |
Q2 2018 | $491,000 | +208.8% | 30,628 | +199.2% | 0.02% | +185.7% |
Q4 2017 | $159,000 | -10.7% | 10,238 | -36.2% | 0.01% | -22.2% |
Q3 2017 | $178,000 | -4.8% | 16,038 | -21.1% | 0.01% | -10.0% |
Q2 2017 | $187,000 | -37.5% | 20,338 | -42.0% | 0.01% | -28.6% |
Q1 2017 | $299,000 | +269.1% | 35,038 | +190.5% | 0.01% | +250.0% |
Q2 2016 | $81,000 | -20.6% | 12,061 | -25.8% | 0.00% | -20.0% |
Q4 2015 | $102,000 | -46.6% | 16,261 | -25.0% | 0.01% | -28.6% |
Q3 2015 | $191,000 | -50.3% | 21,679 | -33.6% | 0.01% | -46.2% |
Q2 2015 | $384,000 | -20.2% | 32,655 | +61.8% | 0.01% | -18.8% |
Q2 2013 | $481,000 | – | 20,184 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |